GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 176
- Registration Number
- NCT03739710
- Locations
- πΈπͺ
GSK Investigational Site, Uppsala, Sweden
Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT03709706
- Locations
- π¬π§
GSK Investigational Site, Manchester, United Kingdom
A Study to Investigate Food Occlusion Efficacy of a Denture Adhesive in Denture Wearers
Phase 4
Completed
- Conditions
- Denture Retention
- Interventions
- Other: No AdhesiveCombination Product: Marketed Denture Adhesive (Super Poligrip Max Seal)
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 49
- Registration Number
- NCT03709810
- Locations
- πΊπΈ
GSK Investigational Site, Fort Wayne, Indiana, United States
A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma
Phase 2
Withdrawn
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03707678
Pooled Analysis of Clinical Data From Six GSK Studies to Investigate the Efficacy of a Dentifrice Containing 67% Weight by Weight (w/w) Sodium Bicarbonate on Gingivitis and Plaque Accumulation
Completed
- Conditions
- GingivitisDental Plaque
- Interventions
- Other: Control DentifriceOther: Sodium bicarbonate
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1601
- Registration Number
- NCT03703245
- Locations
- π¬π§
GSK Investigational Site, Weybridge, Surrey, United Kingdom
Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
- Conditions
- Solid Tumours
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03702036
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
Phase 2
Withdrawn
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03697824
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT03693612
- Locations
- π¨π¦
GSK Investigational Site, Toronto, Ontario, Canada
Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season
Phase 4
Completed
- Conditions
- Influenza, Human
- Interventions
- Other: Passive enhanced safety surveillance
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1060
- Registration Number
- NCT03688620
- Locations
- πͺπΈ
GSK Investigational Site, Sevilla, Spain
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT03681951
- Locations
- πΊπΈ
GSK Investigational Site, Houston, Texas, United States
Β© Copyright 2025. All Rights Reserved by MedPath